"CBSA’s BioWest 2009 brought together a variety of perspectives on bioscience in Colorado and around the world, as well as focusing on innovation and leadership in general. Ginger Graham, the former president and CEO of Amylin Pharmaceuticals, began the day by offering a high level perspective on the future of the bioscience industry. Graham noted that while she believes the 'fundamentals [of bioscience investement] are still in place” given that solutions are still needed in the healthcare market, many firms have shifted their focus temporarily to “survival rather than value creation.'"Link to the Rocky Radar recap
0 comments:
Post a Comment